EFFECTS OF THE ANGIOTENSIN-II RECEPTOR ANTAGONIST LOSARTAN ON 24-HOUR BLOOD-PRESSURE PROFILES OF PRIMARY AND SECONDARY HYPERTENSIVE RATS

被引:47
作者
SCHNECKO, A [1 ]
WITTE, K [1 ]
LEMMER, B [1 ]
机构
[1] UNIV FRANKFURT,CTR PHARMACOL,W-6000 FRANKFURT,GERMANY
关键词
RENIN-ANGIOTENSIN SYSTEM; SPONTANEOUSLY HYPERTENSIVE RATS; TRANSGENIC RATS; LOSARTAN; CIRCADIAN; BLOOD PRESSURE;
D O I
10.1097/00005344-199508000-00006
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Primary and secondary hypertension differ with regard to circadian blood pressure (BP) profiles. To evaluate the contribution of the renin-angiotensin system (RAS) to circadian BP regulation, we studied cardiovascular effects of the angiotensin II (AII) receptor antagonist losartan and the angiotensin-converting enzyme (ACE) inhibitor enalapril in animal models of primary and secondary hypertension after morning and evening dosing. Systolic/diastolic BP (SBP/DBP) and heart rate (HR) were measured telemetrically in spontaneously hypertensive rats (SHR) and transgenic hypertensive rats (TGR[mRen-2]27). Losartan (0.3 to 30 mg/kg) or enalapril maleate (10 mg/kg) were injected intraperitoneally (i.p.) either at 0700 or 1900 h. Baseline SBP/DBP and HR showed significant circadian rhythmicity in both strains. The 24-h means in SBP/DBP were 190/127 mm Hg in SHR and 200/139 mm Hg in TGR. TGR showed a reversed circadian profile in BP, with peaks occurring during the daily resting period, whereas HR peaked at night. Losartan reduced BP dose dependently; reductions in TGR were significantly greater and obtained at 30-fold lower doses than in SHR. Maximum decreases induced by losartan were similar to those induced with enalapril 10 mg/kg. Both drugs reduced BP in TGR more effectively when applied at 0700 than at 1900 h, resulting in a normalized circadian BP profile. Our results demonstrate that the RAS is involved in both the pathomechanism of hypertension and in the inverse circadian BP pressure pattern in TGR.
引用
收藏
页码:214 / 221
页数:8
相关论文
共 31 条
[1]
ACKERMANN H, 1994, BIAS BIOMETRISCHE AN
[2]
FUNCTIONAL VASCULAR RENIN-ANGIOTENSIN SYSTEM IN HYPERTENSIVE TRANSGENIC RATS FOR THE MOUSE RENIN GENE REN-2 [J].
ARRIBAS, S ;
SANCHEZFERRER, CF ;
PEIRO, C ;
PONTE, A ;
SALAICES, M ;
MARIN, J .
GENERAL PHARMACOLOGY, 1994, 25 (06) :1163-1170
[3]
ROLE OF TISSUE RENIN IN THE PATHOPHYSIOLOGY OF HYPERTENSION IN TGR(MREN2)27 RATS [J].
BADER, M ;
ZHAO, Y ;
SANDER, M ;
LEE, MA ;
BACHMANN, J ;
BOHM, M ;
DJAVIDANI, B ;
PETERS, J ;
MULLINS, JJ ;
GANTEN, D .
HYPERTENSION, 1992, 19 (06) :681-686
[4]
CHRONIC KININ RECEPTOR BLOCKADE ATTENUATES THE ANTIHYPERTENSIVE EFFECT OF RAMIPRIL [J].
BAO, G ;
GOHLKE, P ;
QADRI, F ;
UNGER, T .
HYPERTENSION, 1992, 20 (01) :74-79
[5]
BARRETT GL, 1992, KIDNEY INT, V41, pS125
[6]
ANTIHYPERTENSIVE ACTIVITY OF SCH-31846, A NON-SULFHYDRYL ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR [J].
BAUM, T ;
SYBERTZ, EJ ;
WATKINS, RW ;
AHN, HS ;
NELSON, S ;
EYNON, E ;
VANDERVLIET, G ;
PULA, KK ;
SABIN, C ;
DESIDERIO, DM ;
BECKER, FT ;
VEMULAPALLI, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1983, 5 (04) :655-667
[7]
BERENGUER LM, 1991, J HYPERTENS, V9, P1127
[8]
EFFECTS OF BRADYKININ B-2 RECEPTOR ANTAGONISM ON THE HYPOTENSIVE EFFECTS OF ACE-INHIBITION [J].
BOUAZIZ, H ;
JOULIN, Y ;
SAFAR, M ;
BENETOS, A .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (03) :717-722
[9]
ANTIHYPERTENSIVE ACTIVITY OF THE NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, SK-AND-F 108566, IN RATS AND DOGS [J].
BROOKS, DP ;
FREDRICKSON, TA ;
WEINSTOCK, J ;
RUFFOLO, RR ;
EDWARDS, RM ;
GELLAI, M .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1992, 345 (06) :673-678
[10]
PROLONGED ANGIOTENSIN-II ANTAGONISM IN SPONTANEOUSLY HYPERTENSIVE RATS - HEMODYNAMIC AND BIOCHEMICAL CONSEQUENCES [J].
BUNKENBURG, B ;
SCHNELL, C ;
BAUM, HP ;
CUMIN, F ;
WOOD, JM .
HYPERTENSION, 1991, 18 (03) :278-288